Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

Clinically confirmed diagnosis of active atopic dermatitis (AD), according to the revised Hanifin and Rajka criteria
12-month history of AD and had no significant flares in AD for at least 4 weeks before screening
inadequate response to a ≥1 month treatment with topical medications
Atopic dermatitis covering ≥10% of the body surface area
EASI score ≥16
Validated Investigator Global Assessment (VIGA) ≥3
Use of emollient(s) at least 2x daily for 1 week prior to baseline
Negative coronavirus disease (COVID)-19 results at screening

Uncontrolled moderate-to-severe asthma
Uncontrolled diabetes
Stage III or IV cardiac failure
Severe renal condition
Major surgery within 8 weeks of screening
Immunodeficiency and/or receipt of immunosuppressive drugs within 4 weeks of baseline
Use of systemic Janus kinase (JAK) inhibitor within 8 weeks of baseline
Received live or live-attenuated vaccine within 4 weeks of baseline
Prior receipt of RPT193

An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis